Gliptapil M 500mg/50mg Tablet is a combination oral antihyperglycemic agent containing Metformin 500mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which in turn stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The synergistic action of these two agents helps achieve optimal blood glucose regulation in patients inadequately controlled by diet and exercise alone. Gliptapil M is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, headache, and mild hypoglycemia, although the risk is lower compared to other antidiabetic therapies. Regular monitoring of blood glucose levels and renal function is recommended during therapy. This combination tablet offers a convenient and effective option for improved glycemic control in type 2 diabetes mellitus.